Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.137.173.170
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Journal Scan
Oncology

Histology-tailored neoadjuvant chemotherapy not associated with better overall survival in high-risk soft-tissue sarcoma

Posted on

No disease-free or overall survival benefit was found in patients with high-risk soft-tissue sarcoma treated with histology-tailored neoadjuvant chemotherapy versus standard anthracycline/ifosfamide neoadjuvant chemotherapy, according to a study published in the Journal of Clinical Oncology.

-Advertisement-
-Advertisement-

In this randomized, open-label, phase 3 trial, 287 patients with localized high-risk soft-tissue sarcoma of an extremity or trunk wall, including high-grade myxoid liposarcoma (HG-MLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), and undifferentiated pleomorphic sarcoma (UPS), were randomly assigned to receive 3 cycles of anthracycline/ifosfamide neoadjuvant chemotherapy or histology-tailored neoadjuvant chemotherapy. Histology-tailored neoadjuvant chemotherapy regimens included trabectedin in HG-MLPS, gemcitabine plus dacarbazine in LMS, high-dose prolonged-infusion ifosfamide in SS, etoposide plus ifosfamide in MPNST, and gemcitabine plus docetaxel in UPS.

After a median follow-up of 52 months, the projected disease-free survival and overall survival probabilities in the anthracycline/ifosfamide arm were 0.55 and 0.76 at 60 months; in the histology-tailored arm it was 0.47 and 0.66, respectively.

The authors concluded, “that [anthracycline/ifosfamide] should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-risk soft-tissue sarcoma.”

Reference
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38(19):2178-2186. DOI: 10.1200/JCO.19.03289

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-